Sensei Biotherapeutics, Inc.
$31.39
▼
-10.84%
2026-04-21 09:31:01
www.senseibio.com
NCM: SNSE
Explore Sensei Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$42.07 M
Current Price
$31.39
52W High / Low
$36.76 / $5.25
Stock P/E
—
Book Value
$18.24
Dividend Yield
—
ROCE
-119.5%
ROE
-74.01%
Face Value
—
EPS
$-16.72
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
-0.1
Debt / Equity
8.12
Current Ratio
5.06
Quick Ratio
5.06
Forward P/E
-26.69
Price / Sales
—
Enterprise Value
$20.39 M
EV / EBITDA
-0.92
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NextCure, Inc. | $11.7 | — | $41.66 M | — | -145.43% | -1.11% | $15.74 / $3.85 | $9.97 |
| 2. | ADMA Biologics, Inc. | $10.88 | 17.68 | $2.6 B | — | 34.51% | 35.56% | $25.67 / $7.21 | $2.01 |
| 3. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 4. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
| 5. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 6. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 7. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.96 M | -4.85 M | -5.21 M | -7.27 M | -7.32 M | — |
| Net Profit | -4.72 M | -4.57 M | -4.94 M | -6.86 M | -7.77 M | — |
| EPS in Rs | -3.52 | -3.41 | -3.68 | -5.12 | -5.8 | -5.77 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -22.29 M | -31.66 M | -37.06 M | -50.19 M |
| Net Profit | -21.09 M | -30.16 M | -34.1 M | -48.59 M |
| EPS in Rs | -15.73 | -22.5 | -25.44 | -36.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 22.9 M | 45.36 M | 74.37 M | 118.38 M |
| Total Liabilities | 4.31 M | 6.97 M | 9.48 M | 14.97 M |
| Equity | 18.59 M | 38.39 M | 64.89 M | 103.41 M |
| Current Assets | 21.51 M | 41.93 M | 67.25 M | 108.59 M |
| Current Liabilities | 4.25 M | 5.45 M | 5.64 M | 9.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -20.45 M | -24.67 M | -32.02 M | -39.03 M |
| Investing CF | 19.77 M | 22.44 M | 38.41 M | 49.95 M |
| Financing CF | -0.65 M | -0.79 M | -11.17 M | -0.29 M |
| Free CF | -20.47 M | -24.82 M | -32.2 M | -39.35 M |
| Capex | -0.02 M | -0.15 M | -0.18 M | -0.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 11.57% | 29.82% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-17 | 1:0.05 |